יחס שווי פעילות לרווח לפני ריבית, מסים ופחת: Y-mAbs Therapeutics (YMAB)
The price history of Y-mAbs Therapeutics (YMAB) demonstrates an EV/EBITDA ratio of . The business relies on the commercialization of targeted antibodies to combat rare forms of malignant tumors, utilizing radioimmunotherapy to destroy metastases. Y-mAbs Therapeutics (YMAB) possesses a powerful scientific and technical resource in the field of pediatric oncology, while management is currently optimizing expenses and updating the commercial plan to regain shareholder confidence.
YMAB (ymabs.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The development of unique antibodies to combat pediatric brain tumors creates a high barrier to entry for Y-mAbs Therapeutics (YMAB). The company's dynamic EV/EBITDA ratio reflects the enterprise value relative to its operating profit. This multiple measures the payback period of assets, allowing for an assessment of model sustainability amid significant capital expenditures. Low indicator values confirm either an undervalued asset or the risk of capital degradation.
